Media Library

Access photos, images, or videos for stories in development. If you are a member of the working press and need a resource that is not available on this website, please email your request to and we will make every effort to respond as soon as possible. Please read our terms for usage.

Key Facts

updated March 2022

Chief Executive Officer:
New York City
Web Address:
NYSE Listing:
Total Revenues:
$46.4 billion in 2021
R&D Investment:
$11.4 billion in 2021, which included the discovery and development of new medicines for patients
2021 Worldwide Revenues:

REVLIMID® (lenalidomide), $12.8 billion

ELIQUIS® (apixaban), $10.8 billion

OPDIVO®(nivolumab), $7.5 billion

POMALYST® / Imnovid® (pomalidomide), $3.3 billion

ORENCIA® (abatacept), $3.3 billion

SPRYCEL® (dasatinib), $2.1 billion

YERVOY® (ipilimumab), $2.0 billion

ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), $1.2 billion

REBLOZYL® (luspatercept-aamt), $551 million

EMPLICITI® (elotuzumab), $334 million

ABECMA® (idecabtagene vicleucel), $164 million

ZEPOSIA® (ozanimod), $134 million

BREYANZI® (lisocabtagene maraleucel), $87 million

INREBIC® (fedratinib), $74 million

ONUREG® (azacitidine tablets), $73 million

Mature and other brands* $1.9B 

*Includes products that have lost exclusivity in major markets, over-the-counter (OTC) brands and royalty revenue.

Please click on the product links to see the Full Prescribing Information for ABECMA®ABRAXANE®, BREYANZI®ELIQUIS®, EMPLICITI®, INREBIC®, ONUREG®OPDIVO®, ORENCIA®, POMALYST®, REBLOZYL®REVLIMID®SPRYCEL®, YERVOY® and ZEPOSIA® including Boxed WARNINGS for ABECMA®ABRAXANE®BREYANZI®ELIQUIS®INREBIC®, POMALYST®, REVLIMID®, and Boxed WARNINGS for YERVOY® regarding immune-mediated adverse reaction.

Bristol Myers Squibb Corporate B-roll

Overview B-roll

This B-roll includes a collection of footage of Bristol Myers Squibb campus exteriors, corporate signage, research and development, and manufacturing facilities.

Usage Rights & Restrictions: These media assets are free for editorial broadcast, print, online and radio use. They are restricted for other purposes.

Scientific Media Resources >
Disease State Infographics >